06/16/2026
A new era in retinal care is here.
For the first time, patients with Macular Telangiectasia Type 2 (MacTel) have access to an FDA-approved treatment designed to slow disease progression.
Rupan Trikha, M.D., recently performed the first Encelto®️ implant in New Jersey, bringing this breakthrough therapy to patients at Monmouth Retina.
If you or a loved one has been diagnosed with MacTel, there is now a new path forward. Contact us to learn more.